Bangalore : HealthCare Global Enterprises Limited (HCG), the leading specialty healthcare service provider in India focused on oncology on Monday announced the acquisition of an additional 60.9% in Suchirayu Healthcare Solutions, Hubli, thereby becoming a majority stake owner from its existing 17.7% to 78.6%.
Suchirayu owns a state-of-the-art multi-speciality hospital in Hubli with an operational capacity of 110 beds and a potential to scale up to 250 beds. HCG has operated and maintained the said entity’s hospital since August 2017 and had the right to increase its stake up to 80% in July 2022. HCG also owns and operates a standalone Cancer Centre at Hubli, and the acquisition is expected to create synergetic benefits and market leadership in the geography. HCG and the current group of promoter doctors decided to bring HCG on board to collectively enhance the value moving forward. HCG has a successful track record of integrating acquisitions, and this acquisition will be in line with HCG’s strategy going forward. HCG is one of India’s largest oncology-focused private hospital groups, with a significant network of oncology centers located across leading cities and treating thousands of ‘new cancer patients every year.
On the acquisition Dr. BS Ajaikumar Executive Chairman of HCG, said, “HCG continues on its path to optimize capital allocations around Cancer Care and strengthen its pre-eminent position around the length and breadth of the country. M&A has been a core part of our strategy, and we have demonstrated our capability to integrate acquisitions. Having operated Suchirayu for the past four years with successful patient outcomes and desired financial results, acquiring a majority was a logical step in cementing our presence in the region. We are confident that we will be able to derive multiple synergies with this acquisition. Hubli is an emerging geography with great potential, and the acquisition will deliver focused medical care into this micro-market. We continue to explore opportunities in the regional cancer leaders’ space to further consolidate our dominant position.”